Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.53 |
| ▸ | MEN1 | O00255 | 6/20 | 0.53 |
| ▸ | BLM | P54132 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18153585 | 1.00 | KMT2A (0.53) | KMT2AMEN1BLMNPC1RAB9A | |
| SCHEMBL16696289 | 0.86 | PTGS2 (0.54) | KMT2AMEN1NPC1RAB9AMAPT | |
| SCHEMBL15525568 | 0.81 | KMT2A (0.58) | KMT2AMEN1NPC1RAB9AMAPT | |
| SCHEMBL15525567 | 0.81 | KMT2A (0.58) | KMT2AMEN1NPC1RAB9AMAPT | |
| SCHEMBL18983184 | 0.80 | XDH (0.48) | KMT2AMEN1BLMNPC1RAB9A | |
| SCHEMBL16685883 | 0.80 | XDH (0.48) | KMT2AMEN1BLMNPC1RAB9A | |
| SCHEMBL16686072 | 0.79 | GCK (0.43) | KMT2AMEN1NPC1RAB9AMAPT | |
| SCHEMBL18983192 | 0.79 | GCK (0.43) | KMT2AMEN1NPC1RAB9AMAPT | |
| SCHEMBL20112821 | 0.78 | MAPT (0.54) | KMT2AMEN1NPC1RAB9APOLB | |
| SCHEMBL18165781 | 0.78 | NPC1 (0.44) | KMT2AMEN1NPC1RAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118059093-A | Inhibitors of short chain dehydrogenase activity for the treatment of fibrosis | 卡斯西部储备大学 | 2024-05-24 | — | — | CN | disclosed |
| US-20240100026-A1 | INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR PROMOTING NEUROGENESIS AND INHIBITING NERVE CELL DEATH | UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2024-03-28 | — | — | US | disclosed |
| CN-110582277-B | Inhibitors of short-chain dehydrogenase activity for promoting neurogenesis and inhibiting neuronal cell death | 卡斯西部储备大学 | 2023-11-21 | — | — | CN | disclosed |
| US-20230285402-A1 | Compositions and Methods of Modulating Short-Chain Dehydrogenase Activity | UNIV TEXAS (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230136730-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-04 | — | — | US | disclosed |
| US-20210283113-A1 | INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR TREATING FIBROSIS | CASE WESTERN RESERVE UNIVERSITY | 2021-09-16 | — | — | US | disclosed |
| US-20210106587-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | UNIV CASE WESTERN RESERVE (US) | 2021-04-15 | — | — | US | disclosed |
| US-20210100778-A1 | INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR PROMOTING NEUROGENESIS AND INHIBITING NERVE CELL DEATH | THE UNIVERSITY OF IOWA | 2021-04-08 | — | — | US | disclosed |
| US-10945998-B2 | Inhibitors of short-chain dehydrogenase activity for treating fibrosis | CASE WESTERN RESERVE UNIVERSITY (US) | 2021-03-16 | — | — | US | disclosed |
| US-10869871-B2 | Compositions and methods of modulating short-chain dehydrogenase activity | CASE WESTERN RESERVE UNIVERSITY (US) | 2020-12-22 | — | — | US | disclosed |
| EP-3057973-B1 | COMPOSITIONS COMPRISING A 15-PGDH INHIBITOR FOR THE HEALING OF WOUNDS | UNIV CASE WESTERN RESERVE (US) | 2019-09-04 | — | — | EP | disclosed |
| US-20180064694-A1 | INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR TREATING FIBROSIS | CASE WESTERN RESERVE UNIVERSITY | 2018-03-08 | — | — | US | disclosed |
| EP-3283074-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | Case Western Reserve University (US) | 2018-02-21 | — | — | EP | disclosed |
| EP-3267995-A1 | INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR TREATING FIBROSIS | Case Western Reserve University (US) | 2018-01-17 | — | — | EP | disclosed |
| US-9789116-B2 | Compositions and methods of modulating short-chain dehydrogenase activity | CASE WESTERN RESERVE UNIVERSITY (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170173028-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2017-06-22 | — | — | US | disclosed |
| WO-2016168472-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | CASE WESTERN RESERVE UNIVERSITY (US) | 2016-10-20 | — | — | WO | disclosed |
| WO-2016144958-A1 | INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR TREATING FIBROSIS | CASE WESTERN RESERVE UNIVERSITY (US) | 2016-09-15 | — | — | WO | disclosed |
| EP-3057973-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | Case Western Reserve University (US) | 2016-08-24 | — | — | EP | disclosed |
| WO-2015065716-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | CASE WESTERN RESERVE UNIVERSITY (US) | 2015-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230136730-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | HPGD, GCDH, HPGDS | KMT2A 3903/4885MEN1 4461/4885BLM 1999/4885 |
| US-20240100026-A1 | INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR PROMOTING NEUROGENESIS AND INHIBITING NERVE CELL DEATH | HPGD, GCDH, DCX | KMT2A 3226/4885MEN1 4843/4885BLM 4292/4885 |
| US-20210100778-A1 | INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR PROMOTING NEUROGENESIS AND INHIBITING NERVE CELL DEATH | HPGD, GCDH, DCX | KMT2A 3226/4885MEN1 4843/4885BLM 4292/4885 |
| US-20210106587-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | HPGD, GCDH, HPGDS | KMT2A 3903/4885MEN1 4461/4885BLM 1999/4885 |
| US-20230285402-A1 | Compositions and Methods of Modulating Short-Chain Dehydrogenase Activity | HPGD, GCDH, HPGDS | KMT2A 3903/4885MEN1 4461/4885BLM 1999/4885 |
| US-10869871-B2 | Compositions and methods of modulating short-chain dehydrogenase activity | HPGD, GCDH, HPGDS | KMT2A 3903/4885MEN1 4461/4885BLM 1999/4885 |
| US-20180064694-A1 | INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR TREATING FIBROSIS | GCDH, HPGD, UGDH | KMT2A 3603/4885MEN1 4619/4885BLM 1492/4885 |
| US-20210283113-A1 | INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR TREATING FIBROSIS | GCDH, HPGD, UGDH | KMT2A 3603/4885MEN1 4619/4885BLM 1492/4885 |
| US-10945998-B2 | Inhibitors of short-chain dehydrogenase activity for treating fibrosis | GCDH, HPGD, UGDH | KMT2A 3603/4885MEN1 4619/4885BLM 1492/4885 |
| US-20170173028-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | HPGD, GCDH, HPGDS | KMT2A 3903/4885MEN1 4461/4885BLM 1999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.